Biomerica, Inc. (NASDAQ:BMRA) shares rose Wednesday, on word the company’s COVID-19 antigen rapid test can be performed with a nasal swab.
This simple nasal swab, which takes the sample from the front opening of the nose, is less invasive and more comfortable for patients than the deep anterior nasal swab which is typically used. The test is highly portable, cost effective and provides visual results negating the need for any equipment to perform or read the test.
The test also provides results in 15 minutes versus lab-run PCR tests which can take up to three days for results, thereby potentially expediting the process of identifying infectious people and preventing further spread of the virus.
Zack Irani, CEO at Biomerica, commented, "COVID-19 testing will be with us well past the pandemic, and ensuring that health care professionals have a simple, reliable testing solution is imperative. Our nasal swab test is simple to use, accurate and portable.
"It is important to note that while we continue to utilize and apply our diagnostic know-how to COVID-19 tests, our primary focus remains the validation and commercialization of our InFoods ® diagnostic platform.
"We believe that InFoods ® is a revolutionary approach to the diagnosis and treatment of Irritable Bowel Syndrome and other gastrointestinal diseases and we continue to work tirelessly to bring these products to market."
BMRA shares jumped 43 cents, or 12.6%, to $3.84.
